Director, CMC Quality, Pulmovant

Pulmovant is a Roivant-backed clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases. Pulmovant’s first investigational candidate, mosliciguat, is designed to provide a novel, once-daily, inhaled treatment option for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Mosliciguat is a potential first-in-class soluble guanylate cyclase activator with a differentiated mechanism of action currently being evaluated in the Phase 3 PHrontier global clinical trial in PH-ILD, but with potential broad applicability across the PH and ILD disease landscape. 

Pulmovant recently announced positive results from its Phase 2 PHocus study evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. PHocus met both primary and secondary endpoints including the highest ever reported pulmonary vascular resistance (PVR) reduction in any randomized controlled PH trial. The robust results, in conjunction with mosliciguat’s once-daily, inhaled administration and potential first-in-class sGC activator profile, strongly position it as a potential single agent treatment and combination therapy for patients with PH-ILD.  These data represent a significant advancement in a devastating disease that affects ~200,000 patients with no or very limited treatment options. A Phase 3 trial is currently underway. More details can be found in the press release here.

As part of the Roivant family of companies, Pulmovant leverages the power of collaboration and innovation to drive progress.

For more information, please visit https://www.pulmovant.com.

About Roivant:

Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.

Position: Director, CMC Quality

Summary: The Director, CMC Quality will be responsible for providing quality oversight and direction to Pulmovant's vendors to ensure that drug substance, drug product, and finished product are manufactured, tested, released, and distributed in compliance with current Good Manufacturing Practices (cGMPs). This is an individual contributor role within a lean QA team, requiring someone who thrives in a small‑company environment and is comfortable being hands‑on across all aspects of CMC quality. The role demands a strategic yet highly practical approach to quality systems, vendor oversight, and multi‑regional regulatory compliance in support of Pulmovant's global clinical development program. 

Key Duties & Responsibilities:

• Ensure that manufacturing operations at Contract Manufacturing Organizations (CMOs) and partners comply with regulatory requirements and internal Pulmovant quality standards.
• Lead clinical lot disposition and batch record review, ensuring product are released in compliance with Pulmovant procedures, applicable regional requirements, and support QP certification and governance activities at contract manufacturing partners for ex-US clinical trials.
• Oversee GMP Quality Systems activities at external partners, including deviations, investigations, cAPAs, change controls, and OOS/OOT investigations ensuring timely and compliance execution and closure.
• Conduct and document cGMP audits of vendors, CMOs, contract testing laboratories, contract packaging/labeling, and logistics providers. Negotiate and maintain Quality Agreements with external partners.
• Provide quality and technical input to cross-functional project teams, and review internal and external documentation including protocols, reports, test methods, specifications, master batch records, and SOPs.
• Partner with CMC, Supply Chain, and Regulatory Affairs to assess overall product quality performance, identify product-specific quality and compliance risks, and develop risk-mitigation plans.
• Lead quality initiatives including regulatory inspection preparation and ongoing inspection readiness activities.
• Support the review of CMC sections of regulatory submissions, including INDs and IMPDs, and contribute to responses to health authority questions related to manufacturing and quality.

Education and Experience:

• BA/BS degree in Chemistry, Biology, or Life Sciences with at least 8 years of experience in the pharmaceutical industry

Essential Skills and Abilities:

• Demonstrated knowledge of Quality Systems and cGMP within a regulated environment.
• Demonstrated knowledge of Good Distribution Practices.
• Auditing experience is required.
• Demonstrated experience providing quality oversight of CMOs, including audits, batch review, and issue resolution.
• Analytically strong with practical knowledge of how to identify key performance metrics and quality indicators to set targets and identify areas for improvement.
• Proven leadership, negotiation, and conflict management skills with experience influencing across functions and organizations
• Exceptional interpersonal skills with a focus on rapport‑building, active listening, and effective questioning.
• Experience in environments requiring problem‑solving and risk‑based solutions.
• Excellent organizational and time management skills with a high level of attention to detail.
• Excellent verbal and written communication skills; ability to deal with complex problems, determine and evaluate risk, and present recommendations and findings in a clear, concise format.
• Experience in fast paced, start-up environments preferred - able to work comfortably under pressure, frequently changing landscape and tight deadlines.

Pulmovant provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.

We will not accept unsolicited resumes nor outreach from agencies. Please do not send agency resumes to our website or Roivant Sciences and affiliated employees. Thanks!